Phase III clinical trial - VADS

CHECKMATE 651 (CA209-651)
Essai clinique fermé
Public cible
An Open Label, Randomized, Two Arm Phase III Study of Nivolumab in Combination with Ipilimumab versus Extreme Study Regimen (cetuximab + cisplatin/carboplatin + fluorouracil) as First Line Therapy in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck.
Description de l'essai

This study is a phase III trial comparing standard first-line chemotherapy with the combination of nivolumab abd ipilimumab in patients with treatment-naive recurrent head and neck cancer.